Top News from the IASLC 19th World Conference on Lung Cancer 2018
Tecentriq sets the bar in small-cell lung cancer
Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
Top Pharma News of the Week
AstraZeneca’s Imfinzi Cuts Lung Cancer Death by a Third
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look. The Orphan Drug Act of 1983 was created to encourage pharmaceutical companies … Συνεχίστε να διαβάζετε Debate Over the Orphan Drug Act Heats Up.
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases August 14, 2018 Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD). FDA Approves KALYDECO® (ivacaftor) as First and … Συνεχίστε να διαβάζετε Top Pharma News of the Week.
The U.S. Food and Drug Administration (FDA) granted Merck & Co.’s Keytruda another approval, this one in combination with Alimta (pemetrexed) and platinum chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. The approval was based on data from the KEYNOTE-189 Phase III clinical trial. The trial evaluated patients regardless … Συνεχίστε να διαβάζετε Merck’s Keytruda Nabs Another Approval, This One Under FDA’s Real-Time Program.
Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer Bristol-Myers Squibb Company and Tsinghua University have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers. The collaboration brings together Bristol-Myers Squibb and Tsinghua University’s respective scientific expertise and capabilities with … Συνεχίστε να διαβάζετε Top Pharma News of the Week.
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial. About two years ago, AstraZeneca picked up Orphan Drug designation for selumetinib, a MEK 1 and … Συνεχίστε να διαβάζετε AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report.